corporate

English

ttcsid_D91UQTJC77U4M7JJ4T00

__obref

_wingify_test_cookie

_wingify_uuid_v2

_wingify_uuid

_ttp

__hstc

hubspotutk

_wingify_consent

_ga_7N4B2FPHDG

_wingify_ds

_wingify_sn

_fbp

_wingify_s

_gcl_au

ttcsid

__hssrc

__hssc

_tt_enable_cookie

The domain 'openloophealth.com' uses the commercial generic top-level domain (.com) without a subdomain. The registrable portion 'openloophealth' spans 14 characters split between six vowels and eight consonants. Breaking it apart gives 3 words: open, loop, health. Average segment length settles at four characters. No strong language cues emerged from the frequency lists.

html/93/54/935472fe-a0b6-4baa-aa04-9c7bd6d087f2.html.gz

default-src *.facebook.com *.fbcdn.net *.facebook.net 'self' blob:;script-src *.facebook.com *.fbcdn.net *.facebook.net blob: 'self' 'nonce-Vbac4yFf';style-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob: 'unsafe-inline';connect-src *.facebook.com facebook.com *.fbcdn.net *.facebook.net wss://*.facebook.com:* wss://*.fbcdn.net attachment.fbsbx.com *.cdninstagram.com blob: 'self' data: https://edge-chat.facebook.net https://edge-chat-latest.facebook.net wss://edge-chat-latest.facebook.net wss://edge-chat.facebook.net wss://edge-chat.socialplugin.facebook.net wss://edge-chat-latest.socialplugin.facebook.net https://edge-chat.socialplugin.facebook.net https://edge-chat-latest.socialplugin.facebook.net;font-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;img-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;media-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;child-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;frame-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;manifest-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;object-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;worker-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;block-all-mixed-content;upgrade-insecure-requests;report-uri https://www.facebook.com/csp/reporting/?m=c&minimize=0;

frame-ancestors 'self'; report-uri https://send.hsbrowserreports.com/csp/report?resource=web-interactives-embed/static-2.5469/bundles/project.js&cfRay=a0e380e19852c05e-FRA

frame-ancestors 'self'; report-uri https://send.hsbrowserreports.com/csp/report?resource=adsscriptloaderstatic/static-1.3239/bundles/pixels-release.js&cfRay=a1fd3d958f75edb0-IAD

default-src *.facebook.com *.fbcdn.net *.facebook.net 'self' blob:;script-src *.facebook.com *.fbcdn.net *.facebook.net blob: 'self' 'nonce-2FgaXRWo';style-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob: 'unsafe-inline';connect-src *.facebook.com facebook.com *.fbcdn.net *.facebook.net wss://*.facebook.com:* wss://*.fbcdn.net attachment.fbsbx.com *.cdninstagram.com blob: 'self' data: https://edge-chat.facebook.net https://edge-chat-latest.facebook.net wss://edge-chat-latest.facebook.net wss://edge-chat.facebook.net wss://edge-chat.socialplugin.facebook.net wss://edge-chat-latest.socialplugin.facebook.net https://edge-chat.socialplugin.facebook.net https://edge-chat-latest.socialplugin.facebook.net;font-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;img-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;media-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;child-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;frame-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;manifest-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;object-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;worker-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;block-all-mixed-content;upgrade-insecure-requests;report-uri https://www.facebook.com/csp/reporting/?m=c&minimize=0;

frame-ancestors 'self'; report-uri https://send.hsbrowserreports.com/csp/report?resource=web-interactives-container/static-2.5469/bundles/project.js&cfRay=a0e353a23dd79232-FRA

Popup CTA

274c0881ba9e45e544603ffed844ecfd18e6efbc0695089e4e954f61db00d720

d203d37998f40606ce2a1222f5f5b3c471a916e3791a47af7238d04257311a41

a1a09b770a6657e1123e3f771bde213333ca01cf26f369ab8535df85c97e5f5e

2cc8901e59b82e68dff21c3cbdb501fb62e1e2bb898f6f734db5a5d91d9d9ba7

2b57ac8bf01d71df18482b732e6f255969510dd939a1f39f0a670d0be60d2e1f

76248085995cbed6061fa607111f0fcf2f5d6c0128195e593ee79414eba8a494

4b2e432dfecff054a26a536633fef3bdbe5d572f3c69584a000de7403f0c266e

83cae455faf7b745385d8121637597272fba17ee7d52a01760b35db1c23dc5f7

b2930a6b51d16247f7f6e6fa1fe5e0225f7ac19f90f7c550f4ba0ade17dd6a4a

8aa21cd424fadeffa0efe601e04878a31fbc1c5c539d3e21f75dd439a35f7821

6823ca6411e83b1bc5b9c5b4898faaddc1515b99c53c0e663a0564bf9daf25f6

02994f310f032db3cbaffecab32d872a60c1ddf4ec3f0d9e4079be4ed0c64c24

6c9116f2d5900a672bb04bce360fbece4fb794d9e67f3be5097ae129f3285077

dfac10685796259829bc2bd54f8182894f9a992ebfe04bc69d81a4d4bc9a21e8

6e187798f38903d98819498dfa7d58da47db4e8fcfd5f76bb27e6abe90bda262

2c97f49fae7114308ef047ff8f2e56b10f90535a321be68cbe35ddf852e9a982

ee1cefaa59697412f1aede4047372615a2043018195104fcb940fc262d3beb21

428c2c92ec9c573d4e2c88c3ebf2aa8e03d70d2f33c21a42ea2be7205d36c519

80eb347d12bb7f36cba20de6f9be54b47ff0165019e81ce792ebb09dea74a17e

fa68756dca452274c4eb4ca1836bec41c903cbcb87a6562ddf9500cbe5f2c82a

3b4e1e5f356eddedd9dd253e75e0a0913611da79cd80c134f2cfd84542f33dfe

ba7d5e67d6821339ef0d24b5c9c2719b28ccf47c88822d77cbbf8d303fd39e60

4d69965f6586ccc0d2f604b6926a2b42a2ba1895af6fe5f44713e823d1be0782

bda83d88e4e1b2c00bc55f47b182b9a1c6e70b6714c54ddda4fddf939c06dcb9

855230e1321917153b6859521e1ccfab0dce7497f88645e73d7e6db9c4bbe3b1

7b33c169fc503886d0caaac42cb07435f70fbbe630c078e205c406f036f3a9e0

243be6b60c678dea61d1af6f65b5e56bab2c460441d9dbf5df212c5c8613225e

a236defd861c4d5c3daff5f76f774fa8207980aa8df746aefa493ada81fbefef

2a6eb27150e9c27e58f99a64245de8305398375b4f69797ed6b8d53c9a6cb825

a53d317df469e2f812a186a4225088ccd47417af2c500a323f6a32ab0fc19892

9e8d0bce33a76b81e36dae8d8d947b1589880fba4e83238454fd2ce291882719

19427551e8735bb5392932b2586da51f1ae78d376ad06dcfbd8a69f80f2ca1a4

615444555504f99a6d3900e30c2c6e07a0b59c030dc8e35baee1b1c0b6fd5fc4

df96bf0b6ed73f13ebe865501ab1863d77064097275fe8137447a54c58134888

e079fbeab7f3c568b7045eb5b2530087b03df61282e76eed38e995a84c39348a

fedda149a523491e509c60d4a2ab154751caf614c79c3fa8a85e4174e5ae1332

ca498aafc063e63ff441670eb5da9c8bbd0cb7a8768eb865fee22d2d853a4160

417c2fa4ff8cf5e36b1797c558e99b797cf8e9a960ce8e126ccd8de6ff09efca

aa1b7c9dd8de0e0f8d4f5dad497c404cad83427b04746cce8c31f82de291c47b

819d0b424da3c313dcf80411b8fed025d12e705e68bd1163661c4dfcae8f6fba

8da927b6b1240ffca4323fbb2a12c8e5abb541040965c2bc5b7d09a2eb963b02

cac10fef123902fa2e57bf0ffb3b0942e9a4ea6e34dfe50e4777443166a5f310

cb5224674e43d02db0037517f4aa29ba5ce9ddd0672e513cc7289714ba657522

090fe381f7f8879308f8a2b762f8cd04cc733c71c558a76bb1eb49c55be2a276

09b67475f266dbf552159ca9f6b44d9dc3ea04842b2bd6e8b09d74f6b21897d0

aa0b10ed1411ee7e4fe65055dad7aa84c2a86abc35872bf0da6d9828a62d52ff

796de48c9aa90263f4b4587390abadd60767b89f97571acb532ea2a9f968f03e

d181d751c3115f9a5282d3acb523dd861f04cb6a7de55896f444cfb2da3c8160

88d3677f612bfb3894e813e2afe0ea88b3448b2de745c85bd28e9936b0b35344

41793dffa08b5143b2d10ce90c1b069a5d5a32cc6c7006b595e51298aa797cc8

a5b9ad5bc8da22372de541abef7caabc9c13b9eb8acc2454cf8e252168b321a1

7b40d3ce89f3c0ba72f0bc2a954caf093ceec94725dae49c43539eec1785217a

5ee614295b7ab088064260fac3729396add2b2795db5d43bf32d0f39c5c75f8e

a02455592cc5df965ae8161b82104c93ccb74dd7276b0c5972548f5c8d16cf0a

e62c5bf801651aea92ceedcea8d4e8838d1ff82d3252638c970c01df22e99420

bf7106d798538ed3e733f916d60b46c1b32738fc61cb792f1dd15d677f29a54f

248131aca5b1d876bb55caaa0e707fb31a204b545baf3541c62be89e21bbb69f

bc0c2e82e471ce8f75f557a3268028e576822e8f609438e8466df6b3f37d796f

4c9c150927d376928d1352f3975c14ef712608b14d954a5e4fc3d02a867380b9

8536e4b8856eb83636b056dad69f92aa2e50309609cb4e72f14578d6ef9f2acf

fbfd29ed05dc981c667f289d5553d01ee9fd477858a04cdcbf0d181f57ddb5fd

3402f7ad14625e9e784024d3f4ae5c804096bb895df0b9ea6e9312514b87b4ff

a296b20404bd76de76f8caba51582a814882e1b4d275f154831e66257ab0ec30

0a4f1dd170feb89c79c19143c79efb0a7b11224f299ecfc5674832651f007dbe

0973c1d64c88adc8e3c950410cb58b288f72118d5965b78049438deb8f2f9683

fb8bfb853a79856d3cc0813644801077f5310fa32b67dbd281839b31fc6b60cb

ee6bb81f4e9fc030a39a7c71affc4d1f2b900baa4b4c7af83361388d7c39599b

4009527b06902e2fcd3c2ce78c0652caf43bda1783d1577198d0c3919782c607

a7b184efc6db3070eb138216ce988c4adb40b13a54bbbc308b9ff0be71f9e0eb

a2de2e58c50b3a040444955e5bed514b82e241acde87d5586be2336f0097e375

0fd4b9297b1249a8ca29517725ff81db610718a80558c99a2df7f9ad8e853597

7e4d21abcbd5084aff9b115fab65013ac5ffd20f8dc98677334fdbd25021d20b

22e7ad077032eb51daeae35671ed471a2d3877ff4ccdc12e073f63477ae3620b

c38a545d2f636f6b00b959a4eecf804f00f83e1795b8c9c48c737ece4720a616

98d7482ce049e6b977d54e87a53c6f2c6aafafb7fdec357d5ffe93a32187a940

39718eabe59d8df09f941539acfe03b666975c197ab7ccbf64fa24fd6404680a

296792d497654af19649104283d90723f66e04e98718c7c5f53e698f7064376c

74cec3299bbd0a0865933bae0c1a66781a73d9b6b194db603aa90568c70b71d6

fcd405680e1972a9457d6f133892080fef786e622e9cccdfac75bbb0fc2288a5

ea506dcf930499dca2b571fe8fdc246af10e3f1ea53810fe016fc92862d62983

e3259b3675dab4b367d90a043f6b2e921c813ec3e7fa43d99d893cb48fcbb2b2

d61b8e4cb544bd58da80690237283b025c058aea06295497177289aaa982f07f

0e27602f8169fa8fb391ec9cc6af93bd2732e7e21953e3393f4473e0d897039b

b43e6f19640bc4e5def9955c53cfa0f30a01c6b2b7d3d91a311fa5dc78e2a310

c1896b96fc3335034f4ab6389f742133a846c36a13abf561fd31693c78142a2d

06b18d0a622302383f7c9557aaddee29177d159268d12f565ca8c7b164f1dbb2

60df5176526e2c4965d4b85c66bccf567a25b70b7a2c6479baa737077e2aac82

6d863dd6189f0f275bd25712bd29deca634e8140e8dee9850a016762edb6c65f

94b916bba8296e3946b288f14f5e6d424fdd30ba88220ad82e9702de44dfd326

d1dde132e38d10824bd7ef40b91e996fc4186e91168831d1fae30ca62049111d

What The FDA Category 1 vs Category 2 Status Means Today

What Reclassification May Mean for Healthcare Leaders

How OpenLoop Health Approaches Peptide Therapy

You can review the FDA’s compounding framework here.

You can monitor formal federal regulatory updates via the Federal Register here.

4/15/2026
|
6 MINUTE READ
Current State of the Peptide Market and Where it's Headed in Telehealth
Th

4/28/2026
|
10 MINUTE READ
How to Offer a Peptide Therapy Program at Your Business
Learn how to offe

5/4/2026
|
8 MINUTE READ
Pros and Cons of Working with a White-Label Peptide Therapy Partner
Explore

viewport

robots

No peptides have come off the FDA Category 2 list (yet). Here’s what healthcare leaders need to know right now.

description

https://images.ctfassets.net/7b49qn4tvor3/1WTTNs354EJeN4goZvQR9e/7ddb472a420c1fafdde1e1797b66b42a/What_Peptides_Are_Becoming_Legal_in_2026.jpg?w=898&fit=FIT

Cloudflare, Inc.

OPENLOOPHEALTH.COM

Abuse

Admin

Cloudflare-NOC

CLOUDFLARENET

Updated: March, 13 2026 In late 2023, the Food and Drug Administration (FDA) removed 19 peptides from their FDA Category 1 list to FDA Category 2. This was because the FDA identified significant, unresolved patient safety risks, making the 19 peptides ineligible for routine compounding by traditional, 503A pharmacies. However, at the time, some clinicians and compounding pharmacies argued the agency overstepped. On February 27, 2026, while doing an interview on The Joe Rogan Experience, HHS Secretary Robert F. Kennedy Jr. (RFK Jr.) discussed the FDA’s current restrictions on peptides, stating his intention was to make peptides more accessible.  RFK Jr. indicated he is working to overturn the 2023 FDA decision that banned compounding pharmacies from producing certain peptides listed in Category 2. He stated he’d like to move 14 of the 19 peptides currently listed under FDA Category 2 back to FDA Category 1, which would allow them to be compounded by traditional, 503A pharmacies.  What’s important to note is that this reclassification has not yet happened. As of this writing: The FDA has not published formal reclassification guidance. Discussions continue for the 14 peptides under Category 2 Category 2 peptides cannot be used in compounding unless the FDA authorizes their use through rulemaking  The governing regulatory framework remains unchanged. You can review the FDA’s compounding framework here. You can monitor formal federal regulatory updates via the Federal Register here. This article provides clarity on: Which peptides are under discussion What Category 2 status means today What peptides can currently be prescribed under 503A compounding And how healthcare organizations should prepare if reclassification occurs 
 Which 14 Peptides Are Coming Back?
 An official FDA list has not been published yet, but based on industry analysts and regulatory experts, these peptides are considered to be the most likely to return to legal compounding. It’s important to clarify that this is not an official list, as none has been released. It reflects industry-informed predictions only. The peptides frequently being referenced in reclassification conversations include: AOD-9604 BPC-157 Emideltide (DSIP — Delta Sleep-Inducing Peptide)  Epitalon (Epithalamin)  GHK-Cu (Copper Peptide)  Kisspeptin-10 KPV MOTS-C Semax Selank TB-500 (Thymosin Beta-4 Fragment) Thymosin Alpha-1 Despite public discussion, these peptides remain categorized as Category 2 under current FDA policy and are not eligible for patient-specific 503A compounding. What The FDA Category 1 vs Category 2 Status Means Today Under the FDA’s interim bulk substances framework for 503A compounding pharmacies: Category 1: Bulk Drug Substances under evaluation with sufficient supporting safety information; may be compounded while under review by the FDA. Category 2: Bulk Drug Substances that identify as presenting significant safety risks; cannot be used in compounding unless the FDA authorizes their use through rulemaking. Category 3: Bulk Drug Substances lacking sufficient documentation or evidence for the FDA to evaluate them and cannot be compounded as active ingredients. Category 2 substances are specifically identified as raising significant safety concerns. Prescribing and compounding Category 2 peptides places prescribers and 503A compounding pharmacies at risk of federal or state enforcement.  Until final FDA rulemaking  moves these peptides out of Category 2 and into Category 1 their regulatory status remains unchanged. Category 1 Bulk Substances Peptides listed as Category 1 may be compounded by 503A pharmacies with a valid, patient-specific prescription while under FDA review. The 14 peptides discussed above are not currently on that eligible list. Reclassification vs FDA Approval It is critical to understand that reclassification is not the same as FDA approval. Reclassification to Category 1 would allow 503A pharmacies to compound a substance while it remains under FDA evaluation. Reclassification does not mean the peptide has been approved by the FDA as a finished drug product. FDA approval requires formal clinical trials, safety and efficacy review, labeling approval, and manufacturing validation under a New Drug Application (NDA) or Biologics License Application (BLA). Category 1 status simply indicates the substance may be compounded under interim policy — it does not establish proven safety, efficacy, or standardized dosing. Compounded medications are not evaluated or approved by the FDA for safety, efficacy or quality Healthcare leaders are closely monitoring the peptide  regulatory approval pathways. ​​What Healthcare Leaders Need to Know Now Current Regulatory Reality The 14 peptides discussed publicly remain Category 2 substances. The FDA has not issued formal reclassification guidance. Category 2 peptides cannot be used in compounding unless the FDA authorizes their use through rulemaking  The regulatory framework governing bulk substances is unchanged. Healthcare organizations are still monitoring changes in FDA guidance. What Reclassification May Mean for Healthcare Leaders If these peptides formally move to Category 1, leaders might expect both opportunity and complexity across five major areas: 1. Expanded Clinical Pathways Category 1 status would provide clearer regulatory footing and could enable structured, compliant prescribing pathways. For organizations with scalable clinical oversight infrastructure, this could unlock: Program expansion Standardized protocols Increased patient demand Greater legitimacy in the market However, readiness will determine who capitalizes on the opportunity. 2. Supply Chain & Pharmacy Partnerships One of the most significant impacts would occur at the pharmacy level. Potential effects include: Shifts in pharmacy participation Ingredient sourcing constraints Production capacity bottlenecks Quality and sterility verification demands Organizations relying on fragmented or loosely governed pharmacy networks may face disruption. Leaders should evaluate: Diversified sourcing strategies Depth of pharmacy compliance controls Contractual flexibility Real-time regulatory monitoring 3. Margin & Cost Structure Impact Reclassification could affect: Cost of goods Ingredient pricing Pharmacy compounding fees Shipping and cold-chain logistics Reimbursement assumptions As supply stabilizes or demand increases, pricing volatility is likely. Leaders should proactively model: Gross margin sensitivity Program pricing flexibility Inventory risk exposure Cash flow implications 5. Patient Demand & Market Dynamics If regulatory positioning becomes clearer, demand may increase rapidly. But transitional friction — including pharmacy bottlenecks — could create short-term access constraints. Organizations with integrated operations, structured intake, and scalable fulfillment systems will be positioned to meet demand. Others may experience: Backlogs Patient dissatisfaction Refund risk Reputational damage
 How OpenLoop Health Approaches Peptide Therapy Peptide therapy is one of the treatment modalities offered within OpenLoop Health–supported clinical programs. When prescribed, it is delivered within a structured, compliance-driven framework designed to prioritize patient safety, regulatory alignment, and clinical oversight. Our approach includes: Licensed clinician oversight. All prescribing decisions are made by appropriately licensed healthcare providers based on individualized medical evaluation, clinical judgment, and documented medical necessity. Regulatory-aligned pharmacy partnerships. We work with compliant state-licensed 503A compounding pharmacies operating in accordance with applicable federal and state regulations. Lot-level third-party testing. Our partner pharmacies must source their active pharmaceutical ingredients (APIs) from FDA registered manufacturers. The API must be accompanied by a valid Certificate of Analysis which verifies the APIs quality and compliance with regulatory standards and conducts routine and rigorous third-party quality testing to check for potency, sterility, quality and contamination to ensure patient safety in compliance with state and United States Pharmacopeia standards. No Reclassification Has Happened, Yet. The 14 peptides remain Category 2 substances today and they are not currently eligible for routine 503A compounding despite certain public commentary. However, if reclassification does occur, it may create both opportunity and operational strain across clinical programs, pharmacy networks, compliance infrastructure, and financial models. Healthcare leaders who treat this moment as a strategic planning window will be best positioned to adapt if the status changes. 

Here’s what healthcare leaders need to know right now.

OpenLoop Health 

Which Peptides Are Becoming Legal Again?


            window.dataLayer = window.dataLayer || [];
            function gtag(){dataLayer.push(arguments);}
            gtag('js', new Date());
          

OpenLoop is a leading white-label telehealth infrastructure provider, delivering scalable clinical, legal, and financial solutions that empower healthcare organizations to launch and expand their virtual care offerings.

Dr. Jon Lensing

BBB Greater Iowa, Quad Cities, and Siouxland

OpenLoop Health, Inc.

OpenLoop delivers smarter, faster care using AI to streamline clinical workflows, enhance patient support and guide optimized care pathways.

OpenLoop Health

OpenLoop Health – Top White‑label Telehealth Provider

requestAnimationFrame(function(){$RT=performance.now()});

$RB=[];$RV=function(a){$RT=performance.now();for(var b=0;b<a.length;b+=2){var c=a[b],e=a[b+1];null!==e.parentNode&&e.parentNode.removeChild(e);var f=c.parentNode;if(f){var g=c.previousSibling,h=0;do{if(c&&8===c.nodeType){var d=c.data;if("/$"===d||"/&"===d)if(0===h)break;else h--;else"$"!==d&&"$?"!==d&&"$~"!==d&&"$!"!==d&&"&"!==d||h++}d=c.nextSibling;f.removeChild(c);c=d}while(c);for(;e.firstChild;)f.insertBefore(e.firstChild,c);g.data="$";g._reactRetry&&requestAnimationFrame(g._reactRetry)}}a.length=0};
$RC=function(a,b){if(b=document.getElementById(b))(a=document.getElementById(a))?(a.previousSibling.data="$~",$RB.push(a,b),2===$RB.length&&("number"!==typeof $RT?requestAnimationFrame($RV.bind(null,$RB)):(a=performance.now(),setTimeout($RV.bind(null,$RB),2300>a&&2E3<a?2300-a:$RT+300-a)))):b.parentNode.removeChild(b)};$RC("B:0","S:0")

{"props":{"pageProps":{"blog":{"sys":{"id":"7A4tirF1dlk464MFQqCxK5"},"bodyCopy":{"json":{"nodeType":"document","data":{},"content":[{"nodeType":"paragraph","data":{},"content":[{"nodeType":"text","val

(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
                      new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
                      j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
                      'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
                      })(window,document,'script','dataLayer','GTM-TSNCJ6P');

!function(b,e,f,g,a,c,d){b.fbq||(a=b.fbq=function(){a.callMethod?a.callMethod.apply(a,arguments):a.queue.push(arguments)},b._fbq||(b._fbq=a),a.push=a,a.loaded=!0,a.version="2.0",a.queue=[],c=e.createElement(f),c.async=!0,c.src=g,d=e.getElementsByTagName(f)[0],d.parentNode.insertBefore(c,d))}(window,document,"script","https://connect.facebook.net/en_US/fbevents.js");fbq("init","840774865016820");fbq("track","PageView");

clientParamBuilder.processAndCollectAllParams();

fbq("track",google_tag_manager["rm"]["48089506"](42),{currency:google_tag_manager["rm"]["48089506"](43),contents:google_tag_manager["rm"]["48089506"](44),order_id:google_tag_manager["rm"]["48089506"](45),value:google_tag_manager["rm"]["48089506"](46)},{eventID:google_tag_manager["rm"]["48089506"](48)});

fbq("track",google_tag_manager["rm"]["48089506"](51),{currency:google_tag_manager["rm"]["48089506"](52),contents:google_tag_manager["rm"]["48089506"](53),order_id:google_tag_manager["rm"]["48089506"](54),value:google_tag_manager["rm"]["48089506"](55)},{eventID:google_tag_manager["rm"]["48089506"](57)});

fbq("track",google_tag_manager["rm"]["48089506"](60),{currency:google_tag_manager["rm"]["48089506"](61),contents:google_tag_manager["rm"]["48089506"](62),order_id:google_tag_manager["rm"]["48089506"](63),value:google_tag_manager["rm"]["48089506"](64)},{eventID:google_tag_manager["rm"]["48089506"](66)});

fbq("track",google_tag_manager["rm"]["48089506"](69),{currency:google_tag_manager["rm"]["48089506"](70),contents:google_tag_manager["rm"]["48089506"](71),order_id:google_tag_manager["rm"]["48089506"](72),value:google_tag_manager["rm"]["48089506"](73)},{eventID:google_tag_manager["rm"]["48089506"](75)});

fbq("track",google_tag_manager["rm"]["48089506"](77),{currency:google_tag_manager["rm"]["48089506"](78),contents:google_tag_manager["rm"]["48089506"](79),order_id:google_tag_manager["rm"]["48089506"](80),value:google_tag_manager["rm"]["48089506"](81)},{eventID:google_tag_manager["rm"]["48089506"](83)});

Open-Graph-Protocol

HubSpot CMS

Amazon Web Services

HSTS

Amazon CloudFront

AWS WAF

Google Analytics

Contentful

Microsoft Advertising

Linkedin Insight Tag

HubSpot Analytics

Google Tag Manager

Facebook Pixel

Amazon S3

What Peptides Are Becoming Legal in 2026?

js.hs-scripts.com

js.hs-analytics.net

ad.doubleclick.net

Tracking domain: www.googletagmanager.com

www.googletagmanager.com

connect.facebook.net

px.ads.linkedin.com

analytics.tiktok.com

js.hs-banner.com

collect.wingify.net

track.hubspot.com

js.hubspot.com

js.hsadspixel.net

snap.licdn.com

bat.bing.com

✅ Low Risk - https://openloophealth.com/blog/what-peptides-are-becoming-legal-2026

Requests	IP Address	Location	AS Autonomous System
48	104.16.6.65Cloudflare · WAF	United States	AS13335Cloudflare, Inc.
48	54.192.35.129Cloudfront · CDN	United States	AS16509Amazon.com, Inc.
96	2	-	-

Security Scan Report: openloophealth.com

Summary

AI Security Verdict

Safe Website

Safety Factors

Details

Screenshot

Page Load Overview

Language Analysis

Primary Language

Detection Details

Website Classification

Primary Category

All Detected Categories

Detected Features

Domain & IP Information

Detected Technologies14

Content Similarity HashesFor malware variant detection

TLSH (Trend Micro Locality Sensitive Hash)

ssdeep (Context Triggered Piecewise Hashing)

sdhash (Similarity Digest Hashing)

Image Hashes

Perceptual Hashes

Other Hashes

Scan History